{"abstract":"The National Heart, Lung, and Blood Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Retargeted Therapeutics, a corporation incorporated under the laws of the state of Delaware.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2020/05/22/2020-11036.html","cfr_references":[],"citation":"85 FR 31193","comment_url":null,"comments_close_on":"2020-06-08","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Heart, Lung, and Blood on or before June 8, 2020 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2020-11036","effective_on":null,"end_page":31193,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2020/05/22/2020-11036.xml","html_url":"https://www.federalregister.gov/documents/2020/05/22/2020-11036/prospective-grant-of-an-exclusive-patent-license-antibody-based-therapy-for-the-treatment-of-cd20","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2020-11036?publication_date=2020-05-22","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2020-05-22/2020-11036/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":179,"last_updated":"2026-09-22 04:15:07 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2020-05-22/pdf/2020-11036.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2020-11036.pdf?1590065136","publication_date":"2020-05-22","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2020/05/22/2020-11036.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T05:20:35Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":31193,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Antibody-Based Therapy for the Treatment of CD20 Expressing Lymphomas","toc_doc":null,"toc_subject":null,"topics":[],"type":"Notice","volume":85}